<DOC>
	<DOCNO>NCT00072553</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , leucovorin , fluorouracil , oxaliplatin , use different way stop tumor cell divide stop grow die . Celecoxib may stop growth colorectal cancer stop blood flow tumor block enzyme necessary tumor cell growth . Combining chemotherapy celecoxib may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine celecoxib leucovorin , fluorouracil , oxaliplatin treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Celecoxib , Leucovorin , Fluorouracil , Oxaliplatin Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient metastatic colorectal cancer treat celecoxib , leucovorin calcium , fluorouracil , oxaliplatin . Secondary - Determine toxicity regimen patient . - Determine time disease control evaluate progression-free survival patient treat regimen . - Determine salvage surgery rate patient treat regimen . - Determine duration chemotherapy-free interval patient treat regimen . - Determine tolerability regimen patient . - Determine quality life patient treat regimen . OUTLINE : This multicenter study . Patients receive FOLFOX7 chemotherapy comprise oxaliplatin IV 2 hour leucovorin calcium IV 2 hour day 1 fluorouracil IV 46 hour begin day 1 . Patients also receive oral celecoxib twice daily begin day 1 . Treatment repeat every 14 day 6 course absence disease progression unacceptable toxicity . Patients stable respond disease stop treatment . If disease progression occur chemotherapy-free interval , patient receive additional 6 course . Patients respond disease receive least 6 course chemotherapy may undergo surgery . Beginning within 10 week surgery , patient receive simplify LV5FU2 chemotherapy comprise leucovorin calcium IV 2 hour day 1 , fluorouracil IV 46 hour begin day 1 , oral celecoxib twice daily begin day 1 . Treatment repeat every 14 day least 12 course . Quality life assess baseline , course 4 6 , every 2 month thereafter . Patients follow 1 month every 2 month thereafter . PROJECTED ACCRUAL : A total 39 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectum Metastatic disease Inoperable disease ( i.e. , suitable complete carcinological surgical resection ) Measurable disease nonmeasurable disease At least 1 unidimensionally measurable lesion least 20 mm conventional CT scan OR 10 mm spiral CT scan Nonmeasurable disease define lesion , include small lesion truly nonmeasurable disease No CNS metastases No exclusive bone metastases No symptomatic ascites pleural effusion evacuate study entry PATIENT CHARACTERISTICS : Age 18 75 Performance status WHO 02 Life expectancy Not specify Hematopoietic Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 No know significant bleed disorder Hepatic Alkaline phosphatase less 3 time upper limit normal ( ULN ) Renal Creatinine less 1.5 time ULN OR Creatinine clearance least 30 mL/min No uncontrolled hypercalcemia Cardiovascular No congestive heart failure Gastrointestinal No total partial bowel obstruction No active gastric duodenal ulceration gastrointestinal bleeding within past year No active inflammatory bowel disease Other Not pregnant nursing Fertile patient must use effective contraception HIV negative No peripheral sensory neuropathy No known sensitivity celecoxib , COX2 inhibitor , NSAIDs , salicylates , sulfonamides No AIDSrelated illness No active infection No malignancy within past 5 year except adequately treat carcinoma situ cervix basal cell squamous cell skin cancer No severe acute chronic medical psychiatric condition laboratory abnormality would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy metastatic disease Chemotherapy Prior adjuvant chemotherapy allow provide progressionfree interval completion therapy 6 month duration No prior chemotherapy metastatic disease No prior adjuvant oxaliplatin No concurrent chemotherapy Endocrine therapy No concurrent chronic oral IV corticosteroid use ( i.e. , 2 week long duration ) Radiotherapy No concurrent radiotherapy Surgery Not specify Other More 30 day since prior investigational drug No concurrent investigational drug treatments No concurrent prophylactic fluconazole No concurrent chronic fulldose aspirin ( least 325 mg/day ) , nonsteroidal antiinflammatory drug ( NSAIDs ) , cyclooxygenase ( COX ) 2 inhibitor Concurrent lowdose ( cardioprotective ) aspirin ( 80 mg/day equivalent ) allow No concurrent lithium No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
</DOC>